

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional) **D2973**Application Number **09/904,753**Applicant **R b r t T. Ly ns**Filing Date **07/13/2001**Group Art Unit **1615**

## U. S. PATENT DOCUMENTS

EXAMINE R INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	RULING DATE IF APPROPRIATE
<i>LM</i>	4,525,346	06-25-1985	Stark	424	80	09-29-1983
	5,171,526	12-15-1992	Wong et al.	422	28	01-05-1990
	5,200,453	04-06-1993	Janssen	514	399	09-17-1990
	5,830,508	11-03-1998	MacKeen	424	602	01-21-1997

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
<i>LM</i> WO 96/25183	22.08.96	PCT			YES NO
					X

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


<i>LM</i>	1	Maria Bishop, "DG Dispatch-ACR: Topical Cyclosporin A Restores Clear Vision To Sjogren's Syndrome Patients", Doctor's Guide Global Edition, <a href="http://www.pslgroup.com/dg/le96aa.htm">www.pslgroup.com/dg/le96aa.htm</a> , November 3, 2000.
	2	J.H. Lee et al., "High-Level Expression of Antimicrobial Peptide Mediated by a Fusion Partner Reinforcing Formation of Inclusion Bodies", Biochemical and Biophysical Research Communications 277, 575-580, (2000)
	3	Stevenson D., MD et al., "Cyclosporin A Ophthalmic Emulsion in the Treatment of Moderate to Severe Dry Eye Disease", Eye News Late 2000-Richmond Eye Associates from Ophthalmology 5/2000; 107:967-974
	4	Gao J, et al., Abstract of "The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy", Department of Biological Science, Allergan, Inc. Cornea 1998 Nov; 17(6): 654-63
	5	Andrew Acheampong et al., "Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs", Current Eye Research 1999, Vol. 18, No. 2, pp. 91-103
	6	Sall K, et al., Abstract of "Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. ScA Phase 3 Study Group.", Ophthalmology 2000 Apr;107(4): 631-9
	7	Stevenson D., Abstract of "Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.", Ophthalmology 2000 May; 107(5):967-74.
	8	Katsumi Matsuzaki, "Why and how are peptide-lipide interactions utilized for self-defence? Magainins and tachyplesins as archetypes", Biochimica et Biophysica Acta 1462 (1999) 1-10
	9	David Andreu, "Animal Antimicrobial Peptides: An Overview", Biopolymers (Peptide Science), Vol. 47, 415-433 (1998)
	10	Katsumi Matsuzaki, "Magainins as paradigm for the mode of action of pore forming polypeptides", Biochimica et Biophysica Acta 1376 (1998) 391-400
	11	W. Lee Maloy et al., "Structure-Activity Studies on Magainins and Other Host Defense Peptides", Biopolymers (Peptide Science), Vol. 37, 105-122 (1995)
<i>LM</i>	12	Michael Zasloff et al., "Antimicrobial activity of synthetic magainin peptides and several analogues", Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 910-913, February 1988, Microbiology

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to the applicant.

TECH CENTER  
01/29/00  
FEB 05 2000



*L. Mays*

*7/11/03*